References
- Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011 Jul 31;43(9):830–837. doi: 10.1038/ng.892. PMID: 21804550; PMCID: PMC3297422.
- Sengsayadeth S, Savani BN, Oluwole O, et al. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem. 2021 Nov 24;3(Suppl 1):6–10. doi: 10.1002/jha2.338. PMID: 35844299; PMCID: PMC9175669.
- Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 May;24(5):679–690. doi: 10.1038/s41591-018-0016-8. PMID: 29713087; PMCID: PMC6613387.
- Laurent C, Syrykh C, Hamon M, et al. Resistance of B-Cell lymphomas to car t-cell therapy is associated with genomic tumor changes which can result in transdifferentiation. Am J Surg Pathol. 2022 Jun 1;46(6):742–753. doi: 10.1097/PAS.0000000000001834. Epub 2021 Nov 18. PMID: 34799485
- Lee YG, Guruprasad P, Ghilardi G, et al. Modulation of BCL-2 in both t cells and tumor cells to enhance chimeric antigen receptor t-cell immunotherapy against cancer. Cancer Discov. 2022 Oct 5;12(10): 2372–2391. doi: 10.1158/2159-8290.CD-21-1026. PMID: 35904479; PMCID: PMC9547936.
- Ye X, Wang L, Nie M, et al. A single-cell atlas of diffuse large B cell lymphoma. Cell Rep. 2022 Apr 19;39(3):110713. doi: 10.1016/j.celrep.2022.110713. PMID: 35443163
- Wright KT, Weirather JL, Jiang S, et al. Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging. Blood Adv. 2023 Aug 22;7(16):4633–4646. doi: 10.1182/bloodadvances.2023009813. PMID: 37196647; PMCID: PMC10448427.
- Sworder BJ, Kurtz DM, Alig SK, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. 2023 Jan 9;41(1):210–225.e5. doi: 10.1016/j.ccell.2022.12.005. Epub 2022 Dec 29. PMID: 36584673; PMCID: PMC10010070.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10. PMID: 29226797; PMCID: PMC5882485.
- Schuster SJ, Bishop MR, Tam CS, et al. JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma. N Engl J Med. 2019 Jan 3;380(1):45–56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. PMID: 30501490.
- Jo T, Yoshihara S, Okuyama Y, et al. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan. Br J Haematol. 2023 Jul;202(2):256–266. doi: 10.1111/bjh.18831. Epub 2023 Apr 25. PMID: 37096915.
- Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503–511. doi: 10.1038/35000501. PMID: 10676951.
- Özçalımlı A, Erdoğdu İH, Turgutkaya A, et al. The evaluation of gene mutation profiles by next-generation sequencing in diffuse large B-cell lymphoma. Int J Lab Hematol. 2023 Jun;45(3):310–316. doi: 10.1111/ijlh.14012. Epub 2022 Dec 28. PMID: 36576110.
- Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013 Jan 22;110(4): 1398–1403. doi: 10.1073/pnas.1205299110. Epub 2013 Jan 4. PMID: 23292937; PMCID: PMC3557051.